In the case of breast and/or ovarian cancer, the Cardiff laboratory conducts full mutation screening of all 22 relevant exons (45 fragments) of the BRCA1 gene and all 26 relevant exons (40 fragments) of the BRCA2 gene for a cancer-affected relative. This evidence concerns the gene BRCA1 and cancer.